Literature DB >> 25610957

Characterization of co-purified acellular pertussis vaccines.

Yinghua Xu1, Yajun Tan, Catpagavalli Asokanathan, Shumin Zhang, Dorothy Xing, Junzhi Wang.   

Abstract

Whole-cell pertussis vaccines (WPVs) have been completely replaced by the co-purified acellular vaccines (APVs) in China. To date few laboratory studies were reported for co-purified APVs in terms of their antigenic composition and protective immune responses. To further understand the antigenic composition in co-purified APVs, in the present study 2-dimensional gel electrophoresis-based proteomic technology was used to analyze the composition of co-purified APVs. The results showed that besides the main antigens pertussis toxin (PT) and filamentous hemagglutinin (FHA), co-purified APVs also contained pertactin (PRN), fimbriae (FIM) 2and3 and other minor protein antigens. Of the 9 proteins identified, 3 were differentially presented in products from manufacturer 1 and manufacturer 2. Compared with WPVs and purified APVs, co-purified APVs induced a mixed Th1/Th2 immune response with more toward to a Th1 response than the purified APVs in this study. These results hint that different immune mechanisms might be involved in protection induced by co-purified and purified APVs.

Entities:  

Keywords:  2-DE, 2-dimensional gel electrophoresis; APVs, acellular pertussis vaccines; BipA, putative outer membrane ligand binding protein; Co-purified acellular pertussis vaccines; FHA, filamentous hemagglutinin; FIM, fimbriae; PRN, pertactin; PT, pertussis toxin; SHD, single human dose; Sbp, sulfate-binding protein precursor; WPVs, whole-cell pertussis vaccines; bvg, Bordetella virulence regulon; immune responses; protection; proteomic analysis; sphB1, autotransporter subtilisin-like protease

Mesh:

Substances:

Year:  2015        PMID: 25610957      PMCID: PMC4514368          DOI: 10.4161/21645515.2014.988549

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  37 in total

1.  Why do pertussis vaccines fail?

Authors:  James D Cherry
Journal:  Pediatrics       Date:  2012-04-23       Impact factor: 7.124

2.  Pertussis booster vaccine in China.

Authors:  Fengcai Zhu
Journal:  Hum Vaccin       Date:  2011-02-01

3.  Pertussis outbreaks and pertussis vaccines: new insights, new concerns, new recommendations?

Authors:  Gregory A Poland
Journal:  Vaccine       Date:  2012-11-19       Impact factor: 3.641

Review 4.  Acellular pertussis vaccines in China.

Authors:  Lichan Wang; Dianliang Lei; Shumin Zhang
Journal:  Vaccine       Date:  2012-10-19       Impact factor: 3.641

5.  Pertussis cases rise 10-fold among older children and adults in England and Wales.

Authors:  Zosia Kmietowicz
Journal:  BMJ       Date:  2012-07-23

6.  The immunoregulatory role of CD4⁺ FoxP3⁺ CD25⁻ regulatory T cells in lungs of mice infected with Bordetella pertussis.

Authors:  Michelle M Coleman; Conor M Finlay; Barry Moran; Joseph Keane; Pádraic J Dunne; Kingston H G Mills
Journal:  FEMS Immunol Med Microbiol       Date:  2012-01-18

7.  Waning protection after fifth dose of acellular pertussis vaccine in children.

Authors:  Nicola P Klein; Joan Bartlett; Ali Rowhani-Rahbar; Bruce Fireman; Roger Baxter
Journal:  N Engl J Med       Date:  2012-09-13       Impact factor: 91.245

8.  Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort.

Authors:  Maxwell A Witt; Larry Arias; Paul H Katz; Elizabeth T Truong; David J Witt
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

9.  Pertussis resurgence in Toronto, Canada: a population-based study including test-incidence feedback modeling.

Authors:  David N Fisman; Patrick Tang; Tanya Hauck; Susan Richardson; Steven J Drews; Donald E Low; Frances Jamieson
Journal:  BMC Public Health       Date:  2011-09-07       Impact factor: 3.295

10.  Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine.

Authors:  Pádraig J Ross; Caroline E Sutton; Sarah Higgins; Aideen C Allen; Kevin Walsh; Alicja Misiak; Ed C Lavelle; Rachel M McLoughlin; Kingston H G Mills
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

View more
  8 in total

Review 1.  [Recent progress in clinical research on pertussis].

Authors:  Dan-Xia Wu; Qiang Chen; Kun-Ling Shen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2016-09

2.  Molecular epidemiology of Bordetella pertussis and analysis of vaccine antigen genes from clinical isolates from Shenzhen, China.

Authors:  Shuang Wu; Qinghua Hu; Chao Yang; Haijian Zhou; Hongyu Chen; Yanwei Zhang; Min Jiang; Yuxiang He; Xiaolu Shi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-08-18       Impact factor: 3.944

Review 3.  Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines.

Authors:  Kevin Markey; Catpagavalli Asokanathan; Ian Feavers
Journal:  Toxins (Basel)       Date:  2019-07-17       Impact factor: 4.546

4.  Design of a Quantitative LC-MS Method for Residual Toxins Adenylate Cyclase Toxin (ACT), Dermonecrotic Toxin (DNT) and Tracheal Cytotoxin (TCT) in Bordetella pertussis Vaccines.

Authors:  Lisa Szymkowicz; Jeffery Gerard; Benjamin Messham; Wai Wan Vivian Tam; D Andrew James
Journal:  Toxins (Basel)       Date:  2021-10-28       Impact factor: 4.546

5.  A Cross-Sectional Study Revealing the Emergence of Erythromycin-Resistant Bordetella pertussis Carrying ptxP3 Alleles in China.

Authors:  Xiaoying Wu; Qianqian Du; Dongfang Li; Lin Yuan; Qinghong Meng; Zhou Fu; Hongmei Xu; Kaihu Yao; Ruiqiu Zhao
Journal:  Front Microbiol       Date:  2022-07-18       Impact factor: 6.064

6.  Epidemiological and clinical characteristics of pertussis in children and their close contacts in households: A cross-sectional survey in Zhejiang Province, China.

Authors:  Luo-Na Lin; Jin-Si Zhou; Chun-Zhen Hua; Guan-Nan Bai; Yu-Mei Mi; Ming-Ming Zhou
Journal:  Front Pediatr       Date:  2022-08-18       Impact factor: 3.569

7.  Variation in Bordetella pertussis Susceptibility to Erythromycin and Virulence-Related Genotype Changes in China (1970-2014).

Authors:  Ying Yang; Kaihu Yao; Xiang Ma; Wei Shi; Lin Yuan; Yonghong Yang
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

8.  Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making.

Authors:  Sophie J Rhodes; Jeremie Guedj; Helen A Fletcher; Thomas Lindenstrøm; Thomas J Scriba; Thomas G Evans; Gwenan M Knight; Richard G White
Journal:  NPJ Vaccines       Date:  2018-09-17       Impact factor: 7.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.